FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					0. 0		. 00()	00		0.110	лпрапу жег	0. 20 .0								
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [CARA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
<u>Terrillion Scott</u>					Cara Therapeanes, me. [CARA]										Direc	tor	10%	Owner		
															X Officer (give title below)			Othe belo	er (specify w)	
(Last)	(Fii	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year)									Sec'y; Chief Compliance & G.C.				G.C.	
C/O CAF	RA THERA	PEUTICS, INC.			12/28/2018										,	- F				
4 STAMI	FORD PLA	ZA, 107 ELM S	TREET	, 9TH																
FL					1 If	4. If Amandment, Date of Original Filed (Month/Dov/Veer)								- 6	6. Individual or Joint/Group Filing (Check Applicable					
					4. "	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line)					
(Street)															X	Form	filed by One	Reporting Pe	rson	
STAMFO	ORD CT	Γ (06902															e than One R	eporting	
																Perso	UII			
(City)	(St	ate) (Zip)																	
		Tabl	e I - No	on-Deriva	ative	Sec	uritie	s Ac	quired	l, Dis	sposed o	f, or l	Ben	efici	ally C	wne	ed			
1. Title of Security (Instr. 3) 2. Transact Date				Execution Date,			3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4					ount of	6. Ownership Form: Direct	7. Nature of Indirect						
(Month/Day			ıy			,	Code (Instr. 8)		(=) (-,	Beneficiall Owned Fo Reported		cially d Following	(D) or Indirec (I) (Instr. 4)					
						Code V		Amount	(A) or Dries		Price			ted action(s)		(Instr. 4)				
						Code	Ľ	Amount	(D)					3 and 4)						
Common Stock 12/28/20					018		S ⁽¹⁾		3,100 ⁽²⁾ D \$3		\$12.5	51 ⁽³⁾	6,386		D					
		Та	ıble II -	Derivativ											y Ow	ned				
				(e.g., pu	ts, c	alls,	warr	ants,	optio	ns, c	onvertib	le se	curi	ities)						
L. Title of Derivative	2. Conversion	3. Transaction Date			4. Transactio		5. Number		6. Date Exercisable and Expiration Date 7. Title and Amount of				8. Price of Derivative		9. Number of derivative	f 10. Ownershi	11. Nature of Indirect			
Security (Instr. 3)	or Exercise Price of	(Month/Day/Year)	if any (Month/I		Code (3)	Instr.			(Month	/Day/Y	ear)	Secur			Security (Instr. 5)		Securities Beneficially	Form: Direct (D)	Beneficial Ownership	
(Instr. 3) Price of (Month/Day/Year) 8 Derivative Security			Acquire			ired	Underlying Derivative					1		Owned	or Indirec	t (Instr. 4)				
				(A) or Disposed			Security (Instr. and 4)			nstr. 3	Following Reported									
				of (D) (Instr. 3										Transaction(s)					
								and 5)								(111301.4)				
				Γ										nount						
													or Nu	mber						
				,	Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	of Sh	ares						
							1,,,	L'-,			- 310			00						

Explanation of Responses:

- 1. This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person.
- 2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.48 \$12.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

Remarks:

/s/ Darren DeStefano, Attorney-in-Fact 01/02/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.